|
Press Releases |
|
 |
|
Monday, June 23, 2025 |
|
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis |
Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). more info >> |
|
Friday, March 28, 2025 |
|
Hua Medicine Announces 2024 Annual Results |
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. more info >> |
|
Tuesday, March 18, 2025 |
|
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce |
On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. more info >> |
|
Monday, March 3, 2025 |
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters |
On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. more info >> |
|
Saturday, November 30, 2024 |
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
Friday, October 25, 2024 |
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
Friday, August 30, 2024 |
|
Hua Medicine Announces 2024 Interim Results |
Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
Friday, August 25, 2023 |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
Aug 1, 2025 11:00 JST
|
|
|
A Bold New Chapter Begins at CEO SUITE
Aug 1, 2025 10:00 HKT/SGT
|
|
|
Shoucheng's Capital Leap: Zhao Tianyang Drives 2025 Upswing
Aug 1, 2025 09:40 HKT/SGT
|
|
|
Fujitsu starts official development of plus-10,000 qubit superconducting quantum computer targeting completion in 2030
Aug 1, 2025 10:20 JST
|
|
|
GTJAI Successfully Issued the First Publicly Offered Digital Bond of a Chinese Securities Firm
Aug 1, 2025 00:00 HKT/SGT
|
|
|
Champion REIT Hosts ESG-Themed Event for a Third Year, Redefining Value and Sustainable Future of Commercial Properties Through Innovation
Jul 31, 2025 20:10 HKT/SGT
|
|
|
Scipio Capital Advisors Capital Raise puts Alternative Asset Yield Within Reach of Accredited Investors
Jul 31, 2025 19:25 HKT/SGT
|
|
|
Revenue of LEQEMBI(R) (Preliminary Basis)
Jul 31, 2025 18:27 JST
|
|
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 31, 2025 16:48 HKT/SGT
|
|
|
Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet
Jul 31, 2025 16:40 HKT/SGT
|
|
|
Transfer of Sharp Mie Plant No.2 and part of the land at Mie Base
Jul 31, 2025 17:11 JST
|
|
|
TANAKA PRECIOUS METAL GROUP Announces Business Partnership with JEPLAN to Realize a Decarbonized, Circular Society
Jul 31, 2025 15:00 JST
|
|
|
DENSO Announces First Quarter Financial Results
Jul 31, 2025 11:25 JST
|
|
|
Honda Launches All-New Prelude Teaser Page Ahead of Scheduled September 2025 Market Introduction
Jul 31, 2025 11:20 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|